Roche aims to become a “top three player” in obesity, Teresa Graham, CEO of the group’s Pharma unit, said Thursday during a ...

Sanofi’s vaccine sales dipped 2.5% in 2025, with almost all immunization products declining. Nevertheless, CEO Paul Hudson ...

AstraZeneca has risen as one of pharma’s most prolific investors in China, including a $630 million pledge last week for full ...

In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW’s Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and ...

Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life ...

More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment ...

Cellares, which last year became the first company to receive the FDA's new advanced manufacturing technology designation, ...

Onvansertib cut the risk of death or disease progression by 62% versus standard of care, but analysts await more detailed ...

Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as ...

Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...

While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP ...

Phacilitate’s annual event dawns as cell and gene therapies reach a new tipping point: the science has hit new heights just ...